PMID- 38390463
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240224
IS  - 2328-8957 (Print)
IS  - 2328-8957 (Electronic)
IS  - 2328-8957 (Linking)
VI  - 11
IP  - 2
DP  - 2024 Feb
TI  - Longitudinal Analysis of Mpox Virus DNA Detectability From Multiple Specimen 
      Types During Acute Illness: A Cohort Study.
PG  - ofae073
LID - 10.1093/ofid/ofae073 [doi]
LID - ofae073
AB  - BACKGROUND: Longitudinal data on the detectability of monkeypox virus (MPXV) 
      genetic material in different specimen types are scarce. METHODS: We describe 
      MPXV-specific polymerase chain reaction (PCR) results from adults with confirmed 
      mpox infection from Toronto, Canada, including a cohort undergoing weekly 
      collection of specimens from multiple anatomic sites until 1 week after skin 
      lesions had fully healed. We quantified the time from symptom onset to resolution 
      of detectable viral DNA (computed tomography [Ct] >/= 35) by modeling exponential 
      decay in Ct value as a function of illness day for each site, censoring at the 
      time of tecovirimat initiation. RESULTS: Among 64 men who have sex with men, the 
      median (interquartile range [IQR]) age was 39 (32.75-45.25) years, and 49% had 
      HIV. Twenty received tecovirimat. Viral DNA was detectable (Ct < 35) at baseline 
      in 74% of genital/buttock/perianal skin swabs, 56% of other skin swabs, 44% of 
      rectal swabs, 37% of throat swabs, 27% of urine, 26% of nasopharyngeal swabs, and 
      8% of semen samples. The median time to resolution of detectable DNA (IQR) was 
      longest for genital/buttock/perianal skin and other skin swabs at 30.0 
      (23.0-47.9) and 22.4 (16.6-29.4) days, respectively, and shortest for 
      nasopharyngeal swabs and semen at 0 (0-12.1) and 0 (0-0) days, respectively. We 
      did not observe an effect of tecovirimat on the rate of decay in viral DNA 
      detectability in any specimen type (all P > .05). CONCLUSIONS: MPXV DNA 
      detectability varies by specimen type and persists for over 3-4 weeks in skin 
      specimens. The rate of decay did not differ by tecovirimat use in this 
      nonrandomized study.
CI  - (c) The Author(s) 2024. Published by Oxford University Press on behalf of 
      Infectious Diseases Society of America.
FAU - Tan, Darrell H S
AU  - Tan DHS
AUID- ORCID: 0000-0002-3069-2875
AD  - Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
AD  - MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, Dalla Lana School of 
      Public Health, Toronto, Ontario, Canada.
FAU - Pico Espinosa, Oscar
AU  - Pico Espinosa O
AD  - MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
FAU - Matelski, John
AU  - Matelski J
AD  - Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
FAU - Khera, Shreya S
AU  - Khera SS
AD  - MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
FAU - Qamar, Attia
AU  - Qamar A
AD  - Scarborough Health Network, Scarborough, Ontario, Canada.
FAU - Persaud, Reva
AU  - Persaud R
AD  - MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
FAU - Hurst, Jacklyn R
AU  - Hurst JR
AD  - Biological Sciences, Sunnybrook Research Institute, Sunnybrook Hospital, Toronto, 
      Ontario, Canada.
FAU - Ly, Angel
AU  - Ly A
AD  - Toronto High Containment Facility, Temerty Medicine, University of Toronto, 
      Toronto, Ontario, Canada.
FAU - Lam, Jessica
AU  - Lam J
AD  - Toronto High Containment Facility, Temerty Medicine, University of Toronto, 
      Toronto, Ontario, Canada.
FAU - Naghibosadat, Maedeh
AU  - Naghibosadat M
AD  - Biological Sciences, Sunnybrook Research Institute, Sunnybrook Hospital, Toronto, 
      Ontario, Canada.
FAU - Christie, Natasha
AU  - Christie N
AD  - Toronto High Containment Facility, Temerty Medicine, University of Toronto, 
      Toronto, Ontario, Canada.
FAU - Hasso, Maan
AU  - Hasso M
AD  - Public Health Ontario Laboratory, Toronto, Ontario, Canada.
FAU - Gough, Kevin
AU  - Gough K
AD  - Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Taggart, Linda R
AU  - Taggart LR
AD  - Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Tan, Charlie
AU  - Tan C
AD  - Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Ostrowski, Mario
AU  - Ostrowski M
AD  - Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Ma, Huiting
AU  - Ma H
AD  - MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
FAU - Gray-Owen, Scott D
AU  - Gray-Owen SD
AUID- ORCID: 0000-0003-1910-5614
AD  - Toronto High Containment Facility, Temerty Medicine, University of Toronto, 
      Toronto, Ontario, Canada.
AD  - Department of Molecular Genetics, Temerty Medicine, University of Toronto, 
      Toronto, Ontario, Canada.
FAU - Kozak, Robert
AU  - Kozak R
AD  - Biological Sciences, Sunnybrook Research Institute, Sunnybrook Hospital, Toronto, 
      Ontario, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, Ontario, Canada.
FAU - Mishra, Sharmistha
AU  - Mishra S
AD  - Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
AD  - MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, 
      Canada.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management and Evaluation, Dalla Lana School of 
      Public Health, Toronto, Ontario, Canada.
AD  - ICES, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20240207
PL  - United States
TA  - Open Forum Infect Dis
JT  - Open forum infectious diseases
JID - 101637045
PMC - PMC10883290
OTO - NOTNLM
OT  - monkeypox
OT  - mpox
OT  - orthopoxvirus
OT  - polymerase chain reaction
OT  - prospective cohort study
OT  - tecovirimat
COIS- Potential conflicts of interest. D.H.S.T.'s institution has received research 
      support for investigator-initiated research studies from AbbVie and Gilead and 
      support for participation in industry-sponsored clinical trials from Glaxo Smith 
      Kline. All other authors declare no conflicts of interest.
EDAT- 2024/02/23 06:44
MHDA- 2024/02/23 06:45
PMCR- 2024/02/07
CRDT- 2024/02/23 03:59
PHST- 2023/11/30 00:00 [received]
PHST- 2024/02/05 00:00 [accepted]
PHST- 2024/02/23 06:45 [medline]
PHST- 2024/02/23 06:44 [pubmed]
PHST- 2024/02/23 03:59 [entrez]
PHST- 2024/02/07 00:00 [pmc-release]
AID - ofae073 [pii]
AID - 10.1093/ofid/ofae073 [doi]
PST - epublish
SO  - Open Forum Infect Dis. 2024 Feb 7;11(2):ofae073. doi: 10.1093/ofid/ofae073. 
      eCollection 2024 Feb.